MS and COVID-19 challenge: asymptomatic COVID-19 infection during treatment with cladribine
Background The use of disease-modifying therapies (DMTs) in people with multiple sclerosis (pwMS) may affect COVID-19 infection outcomes due to DMTs’ immunomodulatory and immunosuppressive effects on immune response. The yet unknown issues are both the early response to the infection, as well as the...
Gespeichert in:
| Veröffentlicht in: | Neurological sciences 2021-09, Vol.42 (9), p.3533-3535 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 3535 |
|---|---|
| container_issue | 9 |
| container_start_page | 3533 |
| container_title | Neurological sciences |
| container_volume | 42 |
| creator | Seferoğlu, Meral Ethemoğlu, Özlem Turan, Ömer Faruk Siva, Aksel |
| description | Background
The use of disease-modifying therapies (DMTs) in people with multiple sclerosis (pwMS) may affect COVID-19 infection outcomes due to DMTs’ immunomodulatory and immunosuppressive effects on immune response. The yet unknown issues are both the early response to the infection, as well as the post-infection development of immunity against the virus under these treatments due to their interaction with the immune system.
Methods
We report two asymptomatic cases of COVID-19 in patients with relapsing–remitting multiple sclerosis (RRMS) shortly after starting cladribine therapy, both developed anti-SARS-CoV-2 antibody response.
Results
Patients with MS who are under newly initiated treatment with cladribine tablets may experience an asymptomatic COVID-19 infection and they may develop immunity against SARS-CoV-2.
Conclusion
These observations raise the probability that DMTs with immunosuppressive effects, such as cladribine, may be considered as a treatment option for selected MS patients with high disease activity during the COVID-19 pandemic. |
| doi_str_mv | 10.1007/s10072-021-05409-6 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmed_primary_34165650</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2544879455</sourcerecordid><originalsourceid>FETCH-LOGICAL-c474t-76045af9a6bf04779099887053aa46ee2949454e1a0167e1df4064974712914a3</originalsourceid><addsrcrecordid>eNp9kUFP3DAQhS3UqlDaP8ChitRLL4GxM7bjHipVCy1IIA6FXnqwvImza5Q4i-2A-Pf1dhdoe-DiseRvnt_MI-SAwiEFkEdxfbISGC2BI6hS7JA9yhWUFcr61fZOa4m75G2MNwBAkVZvyG6FVHDBYY_8uvhRGN8Ws8ufZ8clVUWzNH1v_cJ-Lkx8GFZpHExyzTPgfGeb5EZftFNwflGkYE0arE_FvUvLoulNG9zcefuOvO5MH-37bd0n199Orman5fnl97PZ1_OyQYmplAKQm04ZMe8ApVSgVF1L4JUxKKxlChVytNQAFdLStkMQqCRKyhRFU-2TLxvd1TQfbNtkK8H0ehXcYMKDHo3T_754t9SL8U7XjFVU0SzwaSsQxtvJxqQHFxvb98bbcYqaccRaZhM8ox__Q2_GKfg8XqZEXalasTXFNlQTxhiD7Z7MUNDr1PQmO52z03-y0yI3ffh7jKeWx7AyUG2AuFov3obnv1-Q_Q3SM6Hw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2568398925</pqid></control><display><type>article</type><title>MS and COVID-19 challenge: asymptomatic COVID-19 infection during treatment with cladribine</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>Seferoğlu, Meral ; Ethemoğlu, Özlem ; Turan, Ömer Faruk ; Siva, Aksel</creator><creatorcontrib>Seferoğlu, Meral ; Ethemoğlu, Özlem ; Turan, Ömer Faruk ; Siva, Aksel</creatorcontrib><description>Background
The use of disease-modifying therapies (DMTs) in people with multiple sclerosis (pwMS) may affect COVID-19 infection outcomes due to DMTs’ immunomodulatory and immunosuppressive effects on immune response. The yet unknown issues are both the early response to the infection, as well as the post-infection development of immunity against the virus under these treatments due to their interaction with the immune system.
Methods
We report two asymptomatic cases of COVID-19 in patients with relapsing–remitting multiple sclerosis (RRMS) shortly after starting cladribine therapy, both developed anti-SARS-CoV-2 antibody response.
Results
Patients with MS who are under newly initiated treatment with cladribine tablets may experience an asymptomatic COVID-19 infection and they may develop immunity against SARS-CoV-2.
Conclusion
These observations raise the probability that DMTs with immunosuppressive effects, such as cladribine, may be considered as a treatment option for selected MS patients with high disease activity during the COVID-19 pandemic.</description><identifier>ISSN: 1590-1874</identifier><identifier>ISSN: 1590-3478</identifier><identifier>EISSN: 1590-3478</identifier><identifier>DOI: 10.1007/s10072-021-05409-6</identifier><identifier>PMID: 34165650</identifier><language>eng</language><publisher>Cham: Springer International Publishing</publisher><subject>Antibody response ; Asymptomatic ; Cladribine ; Cladribine - therapeutic use ; Coronaviruses ; COVID-19 ; Humans ; Immune response ; Immunomodulation ; Immunosuppressive Agents - therapeutic use ; Infections ; Medicine ; Medicine & Public Health ; Multiple sclerosis ; Multiple Sclerosis - drug therapy ; Multiple Sclerosis - epidemiology ; Multiple Sclerosis, Relapsing-Remitting - drug therapy ; Neurology ; Neuroradiology ; Neurosciences ; Neurosurgery ; Pandemics ; Patients ; Psychiatry ; SARS-CoV-2 ; Severe acute respiratory syndrome coronavirus 2</subject><ispartof>Neurological sciences, 2021-09, Vol.42 (9), p.3533-3535</ispartof><rights>Fondazione Società Italiana di Neurologia 2021</rights><rights>2021. Fondazione Società Italiana di Neurologia.</rights><rights>Fondazione Società Italiana di Neurologia 2021.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c474t-76045af9a6bf04779099887053aa46ee2949454e1a0167e1df4064974712914a3</citedby><cites>FETCH-LOGICAL-c474t-76045af9a6bf04779099887053aa46ee2949454e1a0167e1df4064974712914a3</cites><orcidid>0000-0003-3858-0306</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10072-021-05409-6$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s10072-021-05409-6$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>230,314,776,780,881,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34165650$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Seferoğlu, Meral</creatorcontrib><creatorcontrib>Ethemoğlu, Özlem</creatorcontrib><creatorcontrib>Turan, Ömer Faruk</creatorcontrib><creatorcontrib>Siva, Aksel</creatorcontrib><title>MS and COVID-19 challenge: asymptomatic COVID-19 infection during treatment with cladribine</title><title>Neurological sciences</title><addtitle>Neurol Sci</addtitle><addtitle>Neurol Sci</addtitle><description>Background
The use of disease-modifying therapies (DMTs) in people with multiple sclerosis (pwMS) may affect COVID-19 infection outcomes due to DMTs’ immunomodulatory and immunosuppressive effects on immune response. The yet unknown issues are both the early response to the infection, as well as the post-infection development of immunity against the virus under these treatments due to their interaction with the immune system.
Methods
We report two asymptomatic cases of COVID-19 in patients with relapsing–remitting multiple sclerosis (RRMS) shortly after starting cladribine therapy, both developed anti-SARS-CoV-2 antibody response.
Results
Patients with MS who are under newly initiated treatment with cladribine tablets may experience an asymptomatic COVID-19 infection and they may develop immunity against SARS-CoV-2.
Conclusion
These observations raise the probability that DMTs with immunosuppressive effects, such as cladribine, may be considered as a treatment option for selected MS patients with high disease activity during the COVID-19 pandemic.</description><subject>Antibody response</subject><subject>Asymptomatic</subject><subject>Cladribine</subject><subject>Cladribine - therapeutic use</subject><subject>Coronaviruses</subject><subject>COVID-19</subject><subject>Humans</subject><subject>Immune response</subject><subject>Immunomodulation</subject><subject>Immunosuppressive Agents - therapeutic use</subject><subject>Infections</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Multiple sclerosis</subject><subject>Multiple Sclerosis - drug therapy</subject><subject>Multiple Sclerosis - epidemiology</subject><subject>Multiple Sclerosis, Relapsing-Remitting - drug therapy</subject><subject>Neurology</subject><subject>Neuroradiology</subject><subject>Neurosciences</subject><subject>Neurosurgery</subject><subject>Pandemics</subject><subject>Patients</subject><subject>Psychiatry</subject><subject>SARS-CoV-2</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><issn>1590-1874</issn><issn>1590-3478</issn><issn>1590-3478</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp9kUFP3DAQhS3UqlDaP8ChitRLL4GxM7bjHipVCy1IIA6FXnqwvImza5Q4i-2A-Pf1dhdoe-DiseRvnt_MI-SAwiEFkEdxfbISGC2BI6hS7JA9yhWUFcr61fZOa4m75G2MNwBAkVZvyG6FVHDBYY_8uvhRGN8Ws8ufZ8clVUWzNH1v_cJ-Lkx8GFZpHExyzTPgfGeb5EZftFNwflGkYE0arE_FvUvLoulNG9zcefuOvO5MH-37bd0n199Orman5fnl97PZ1_OyQYmplAKQm04ZMe8ApVSgVF1L4JUxKKxlChVytNQAFdLStkMQqCRKyhRFU-2TLxvd1TQfbNtkK8H0ehXcYMKDHo3T_754t9SL8U7XjFVU0SzwaSsQxtvJxqQHFxvb98bbcYqaccRaZhM8ox__Q2_GKfg8XqZEXalasTXFNlQTxhiD7Z7MUNDr1PQmO52z03-y0yI3ffh7jKeWx7AyUG2AuFov3obnv1-Q_Q3SM6Hw</recordid><startdate>20210901</startdate><enddate>20210901</enddate><creator>Seferoğlu, Meral</creator><creator>Ethemoğlu, Özlem</creator><creator>Turan, Ömer Faruk</creator><creator>Siva, Aksel</creator><general>Springer International Publishing</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88G</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>K9-</scope><scope>K9.</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>M2M</scope><scope>PHGZM</scope><scope>PHGZT</scope><scope>PJZUB</scope><scope>PKEHL</scope><scope>PPXIY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-3858-0306</orcidid></search><sort><creationdate>20210901</creationdate><title>MS and COVID-19 challenge: asymptomatic COVID-19 infection during treatment with cladribine</title><author>Seferoğlu, Meral ; Ethemoğlu, Özlem ; Turan, Ömer Faruk ; Siva, Aksel</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c474t-76045af9a6bf04779099887053aa46ee2949454e1a0167e1df4064974712914a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Antibody response</topic><topic>Asymptomatic</topic><topic>Cladribine</topic><topic>Cladribine - therapeutic use</topic><topic>Coronaviruses</topic><topic>COVID-19</topic><topic>Humans</topic><topic>Immune response</topic><topic>Immunomodulation</topic><topic>Immunosuppressive Agents - therapeutic use</topic><topic>Infections</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Multiple sclerosis</topic><topic>Multiple Sclerosis - drug therapy</topic><topic>Multiple Sclerosis - epidemiology</topic><topic>Multiple Sclerosis, Relapsing-Remitting - drug therapy</topic><topic>Neurology</topic><topic>Neuroradiology</topic><topic>Neurosciences</topic><topic>Neurosurgery</topic><topic>Pandemics</topic><topic>Patients</topic><topic>Psychiatry</topic><topic>SARS-CoV-2</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Seferoğlu, Meral</creatorcontrib><creatorcontrib>Ethemoğlu, Özlem</creatorcontrib><creatorcontrib>Turan, Ömer Faruk</creatorcontrib><creatorcontrib>Siva, Aksel</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest Psychology</collection><collection>ProQuest Central (New)</collection><collection>ProQuest One Academic (New)</collection><collection>ProQuest Health & Medical Research Collection</collection><collection>ProQuest One Academic Middle East (New)</collection><collection>ProQuest One Health & Nursing</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Neurological sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Seferoğlu, Meral</au><au>Ethemoğlu, Özlem</au><au>Turan, Ömer Faruk</au><au>Siva, Aksel</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>MS and COVID-19 challenge: asymptomatic COVID-19 infection during treatment with cladribine</atitle><jtitle>Neurological sciences</jtitle><stitle>Neurol Sci</stitle><addtitle>Neurol Sci</addtitle><date>2021-09-01</date><risdate>2021</risdate><volume>42</volume><issue>9</issue><spage>3533</spage><epage>3535</epage><pages>3533-3535</pages><issn>1590-1874</issn><issn>1590-3478</issn><eissn>1590-3478</eissn><abstract>Background
The use of disease-modifying therapies (DMTs) in people with multiple sclerosis (pwMS) may affect COVID-19 infection outcomes due to DMTs’ immunomodulatory and immunosuppressive effects on immune response. The yet unknown issues are both the early response to the infection, as well as the post-infection development of immunity against the virus under these treatments due to their interaction with the immune system.
Methods
We report two asymptomatic cases of COVID-19 in patients with relapsing–remitting multiple sclerosis (RRMS) shortly after starting cladribine therapy, both developed anti-SARS-CoV-2 antibody response.
Results
Patients with MS who are under newly initiated treatment with cladribine tablets may experience an asymptomatic COVID-19 infection and they may develop immunity against SARS-CoV-2.
Conclusion
These observations raise the probability that DMTs with immunosuppressive effects, such as cladribine, may be considered as a treatment option for selected MS patients with high disease activity during the COVID-19 pandemic.</abstract><cop>Cham</cop><pub>Springer International Publishing</pub><pmid>34165650</pmid><doi>10.1007/s10072-021-05409-6</doi><tpages>3</tpages><orcidid>https://orcid.org/0000-0003-3858-0306</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1590-1874 |
| ispartof | Neurological sciences, 2021-09, Vol.42 (9), p.3533-3535 |
| issn | 1590-1874 1590-3478 1590-3478 |
| language | eng |
| recordid | cdi_pubmed_primary_34165650 |
| source | MEDLINE; Springer Nature - Complete Springer Journals |
| subjects | Antibody response Asymptomatic Cladribine Cladribine - therapeutic use Coronaviruses COVID-19 Humans Immune response Immunomodulation Immunosuppressive Agents - therapeutic use Infections Medicine Medicine & Public Health Multiple sclerosis Multiple Sclerosis - drug therapy Multiple Sclerosis - epidemiology Multiple Sclerosis, Relapsing-Remitting - drug therapy Neurology Neuroradiology Neurosciences Neurosurgery Pandemics Patients Psychiatry SARS-CoV-2 Severe acute respiratory syndrome coronavirus 2 |
| title | MS and COVID-19 challenge: asymptomatic COVID-19 infection during treatment with cladribine |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-18T23%3A07%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=MS%20and%20COVID-19%20challenge:%20asymptomatic%20COVID-19%20infection%20during%20treatment%20with%20cladribine&rft.jtitle=Neurological%20sciences&rft.au=Sefero%C4%9Flu,%20Meral&rft.date=2021-09-01&rft.volume=42&rft.issue=9&rft.spage=3533&rft.epage=3535&rft.pages=3533-3535&rft.issn=1590-1874&rft.eissn=1590-3478&rft_id=info:doi/10.1007/s10072-021-05409-6&rft_dat=%3Cproquest_pubme%3E2544879455%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2568398925&rft_id=info:pmid/34165650&rfr_iscdi=true |